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In January 2006, the Clinical and Laboratory Standards Institute (CLSI) updated breakpoints for vanco-
mycin susceptibility testing for Staphylococcus aureus such that an MIC greater than 2 mg/liter was considered
to represent nonsusceptibility to vancomycin. Previously, an MIC of 4 mg/liter had been considered to
represent susceptibility. Additionally, in 2009, the CLSI altered the guidelines for staphylococci such that disk
diffusion was no longer an acceptable means for testing vancomycin susceptibility in these organisms. To
accommodate the change in breakpoints and methodological updates, we designed a medium consisting of
brain heart infusion agar with 3 mg/liter vancomycin (BHI-V3) to screen for isolates of S. aureus with reduced
susceptibility to vancomycin. We challenged this medium using a previously characterized collection of 100
isolates of S. aureus, including 55 vancomycin-susceptible isolates and 45 isolates representing vancomycin-
intermediate strains of S. aureus (VISA) (with vancomycin MICs of 4 mg/liter or greater). All of the VISA
isolates grew on the agar, for 100% sensitivity. Nineteen vancomycin-susceptible isolates also grew on the agar,
for 65% specificity. We then incorporated BHI-V3 into clinical practice. In the first 60 days postimplementa-
tion, we identified 17 potential VISA isolates out of 421 S. aureus isolates tested. Thirteen out of the 17 were
confirmed to represent VISA isolates. In light of the excellent sensitivity of this medium, we recommend that
clinical laboratories incorporate BHI-V3 to screen for vancomycin-nonsusceptible isolates of S. aureus.
At the site of this study, 60 to 70% of infections in which
Staphylococcus aureus is the etiologic agent are caused by
methicillin-resistant S. aureus (MRSA). For these infec-
tions, vancomycin is considered the mainstay of antimicro-
bial therapy. The ability to accurately identify isolates of S.
aureus with reduced susceptibility to vancomyin is para-
mount for a successful clinical outcome.
Until recently, strains of S. aureus with reduced susceptibility
to vancomycin could be detected using a screening medium
consisting of brain heart infusion agar (BHI) supplemented
with 6 mg/liter vancomycin (BHI-V6). The medium is inocu-
lated with 10 l of a 0.5 McFarland standard suspension of the
organism and incubated at 35 to 37°C for 24 h. Strains with
reduced susceptibility to vancomycin demonstrate growth of
one or more colonies after 24 h of incubation (1, 2, 8, 9).
However, as of January 2006, the Clinical and Laboratory
Standard Institute (CLSI) breakpoints for vancomycin suscep-
tibility for S. aureus were updated such that strains with an
MIC greater than 2 mg/liter were considered to be nonsuscep-
tible to vancomycin, where those with an MIC of 4 mg/liter had
previously been considered to be vancomycin susceptible (1–
4). As a vancomycin MIC of 4 to 8 mg/liter is considered to
represent intermediate susceptibility, the use of an agar me-
dium such as BHI-V6 as a means to screen for vancomycin-
intermediate strains of S. aureus (VISA) is not adequate for
this purpose, as those strains having a vancomycin MIC greater
than 2 but less than 6 mg/liter are not detected by this method.
To accommodate the change in breakpoints, we designed a
screening medium consisting of BHI with 3 mg/liter vancomy-
cin (BHI-V3). BHI-V3 was manufactured for our laboratory by
Remel (Lenexa, KS). A noninhibitory pink dye, amaranth, was
added to the agar to assist in rapid visual differentiation of it
from other screening agars in the laboratory, such as the 6
mg/liter vancomycin screening agar (yellow) and/or the oxacil-
lin screening agar (clear). The agar is inoculated using the
same method as for the BHI-V6 medium: 10 l of a 0.5 Mc-
Farland standard suspension of organism is added to the agar
and incubated for 24 h at 35 to 37°C. Several isolates can be
placed onto one plate. For quality control purposes, Entero-
coccus faecalis ATCC 29212 was used as a positive growth
control. This organism is the negative growth control for the 6
mg/liter vancomycin screening agar and has an MIC of 4 mg/
liter by Etest in our laboratory. S. aureus ATCC 29213 was
used as a negative growth control and has an MIC of 2 mg/liter
by Etest in our laboratory. These organisms were chosen as
quality control isolates because they bracket the desired con-
centration range of the agar. Any growth on BHI-V3 was
interpreted as positive after confirmation that the isolate was S.
aureus. Any isolate that grew on BHI-V3 was tested directly
from this medium for vancomycin MIC confirmation, or, if
there was not sufficient growth to do so, the isolate was sub-
cultured to another 3 mg/liter BHI-V3 medium prior to per-
formance of susceptibility testing to maintain vancomycin se-
lective pressure.
In the initial evaluation, we challenged the BHI V3 with
eight clinical isolates of E. casseliflavus and E. gallinarum,
which intrinsically have a vancomycin-intermediate phenotype.
All of these isolates grew on the screening agar and had a
vancomycin MIC of 6 or 8 mg/liter, as determined by Etest.
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Then, the ability of BHI-V3 medium to detect isolates of S.
aureus with reduced vancomycin susceptibility was verified us-
ing a previously characterized collection of S. aureus isolates
with MICs to vancomycin ranging from 0.5 to 8 mg/liter (7).
The vancomycin MIC for these strains was determined by the
Centers for Disease Control and Prevention (CDC) using
CLSI reference broth microdilution (7). The MIC that was
used for the purpose of deciding whether these isolates exhib-
ited full or intermediate susceptibility to vancomycin was based
on the Difco broth microdilution result. The collection in-
cluded 55 vancomycin-susceptible isolates (i.e., with a vanco-
mycin MIC of 2 mg/liter or less) and 45 vancomycin-interme-
diate isolates (VISA) with a vancomycin MIC of 4 or 8 mg/
liter. For the purpose of this analysis, the MIC results of the
strain collection were coded and not revealed until the testing
was complete.
All of the VISA isolates grew on the BHI-V3 agar, for 100%
sensitivity for this screening method (Table 1). This is a signif-
icant improvement in sensitivity over what has been reported
for several other methods for the detection of VISA isolates.
For example, Swenson and colleagues have previously re-
ported that BHI-V6 agar failed to detect 33% (12 of 36) of
VISA isolates with an MIC of 4 mg/liter (7). Other methods
that have shown poor sensitivity for the detection of VISA
include the use of Kirby-Bauer disk diffusion, the Trek Sensi-
titre broth microdilution panel, the Vitek Legacy, and the
Vitek2 GP61 and GP67 antimicrobial susceptibility cards (7,
10). The Etest has previously been demonstrated to be sensi-
tive for detection of VISA, but it did categorize one of 45
VISA isolates as vancomycin susceptible in a recent study (7).
Although BHI-V3 has the excellent sensitivity that is desir-
able in a screening assay, there were 19 vancomycin-susceptible
isolates that grew on the medium, corresponding to 65% spec-
ificity (Table 1). One of the susceptible isolates growing on
BHI-V3 had a vancomycin MIC of 0.5 mg/liter, another had an
MIC of 1 mg/liter, and 17 of the discrepant isolates had an
MIC of 2 mg/liter. However, as the agar has a vancomycin
concentration of 3 mg/liter, we postulated that since MIC
methods are performed using doubling dilutions, it was possi-
ble that some of the isolates with a broth microdilution MIC of
2 mg/liter may actually have an MIC greater than 2 mg/liter but
less than 4 mg/liter, the next highest doubling dilution. To
examine this question, we performed MIC analysis for the 17
discrepant isolates by the use of Etest (bioMe´rieux, Durham,
NC) to identify isolates having a vancomycin MIC between 2
and 4 mg/liter. Of the 17 isolates, three had a vancomycin MIC
of 3 mg/liter by Etest, and one of these had a vancomycin MIC
of 3 mg/liter by Etest and an MIC of 4 mg/liter by broth
reference microdilution (BMD) (BBL) and agar dilution (Ta-
ble 2). Of the remaining 14 isolates, one had an MIC of 4
mg/liter by agar dilution as performed by Swenson et al. (7;
Table 2). If these four isolates are considered to represent
“true positives,” the specificity of BHI-V3 increases to 71%. As
we and others have previously demonstrated, MIC testing
for vancomycin is method dependent (6, 7) and so it is
difficult to determine the true specificity of BHI-V3 for
isolates with a vancomycin MIC very close to the breakpoint
between susceptible and intermediate, but it does appear
that this is the range where BHI-V3 performs most poorly
with regard to specificity. It is also possible that the poor
specificity of the medium reflects the detection of heterore-
sistant S. aureus (hVISA) strains that are not readily de-
tected by the comparator methods.
Subsequent to verifying the performance of BHI-V3 agar on a
characterized set of isolates, we incorporated the medium into
routine use in our laboratory to test all clinical isolates of S. aureus
for vancomycin nonsusceptibility. During the first 60 days of use,
we identified 17 potential VISA out of 421 S. aureus isolates
tested using BHI-V3. Those isolates that grew on BHI-V3 were
characterized using Kirby-Bauer disk diffusion with a 30-g van-
comycin disk (Becton Dickinson BBL, Sparks, MD), vancomycin
Etest strips, Sensititre GPALL (Trek Diagnostic Systems, Cleve-
land OH) (vancomycin MIC range from 0.25 to 32 mg/liter),
Microscan Pos MIC panel type 26 (Siemens Healthcare Diagnos-
tics, Deerfield, IL) (vancomycin MIC range from 0.25 to 16 mg/
liter), and the Vitek2 AST-GP67 card (bioMe´rieux) (MIC range
from 0.25 to 32 mg/liter) (Table 3). We observed variable sensi-
tivity for each of the methods with regard to VISA detection. For
the purpose of calculating sensitivity and specificity, isolates that
had an MIC of 4 or 8 by broth microdilution or of 2 to 8 by
Etest were considered to represent VISA. The previous CLSI
disk diffusion susceptibility breakpoint for vancomycin of 15 mm
or greater would have misclassified all of the VISA isolates as
being vancomycin susceptible. Thirteen out of the 17 isolates were
confirmed to be VISA strains when BHI-V3 was implemented
into routine clinical use, for an overall specificity of 99%. Mi-
croscan had the highest sensitivity (92%), failing to detect only
one VISA strain, followed by Etest (85% sensitive) and then
Sensititre (54% sensitive). Vitek2 GP67 had the worst sensitivity,
detecting only 1 of the 13 VISA isolates. It should be noted,
however, that the VISA isolates did have a GP67 vancomycin
MIC of 2 mg/liter, whereas in our experience S. aureus isolates
typically have a vancomycin MIC of 0.5 mg/liter when tested
TABLE 1. Performance of BHI-V3 with previously characterized





No growth on BHI-V3
(no. of isolates) Total
8 10 0 10
4 35 0 35
2 17 7 24
1 1 27 28
0.5 1 2 3
a Vancomycin MIC determined by CLSI broth reference microdilution
(BMD) using Difco Mueller-Hinton broth.
TABLE 2. Results of testing with other susceptibility methods for
previously characterized strains of S. aureus with a vancomycin
MIC of 2 mg/liter and growth on BHI-V3
Vancomycin MIC (mg/liter)
No. of isolates BMD BBLa BMD Difcoa Agar dilutiona Etestb
13 2 2 2 2
2 2 2 2 3
1 4 2 4 3
1 2 2 4 2
a Vancomycin MIC determined at the CDC.
b Vancomycin MIC determined at Washington University.
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with this methodology (personal observation). This would suggest
that laboratories using the GP67 AST card for vancomycin sus-
ceptibility testing of S. aureus should consider additional testing to
rule out VISA when an MIC of 2 mg/liter is generated and/or the
concomitant use of a screening medium such as BHI-V3 to en-
sure detection of VISA isolates.
In light of the excellent sensitivity of BHI-V3 for detection
of VISA isolates, we recommend that clinical laboratories use
this medium to screen all isolates of S. aureus for nonsuscep-
tibility to vancomycin. If the isolate does not grow on this
medium, one can be assured that the isolate is vancomycin
susceptible and can report it as such. Any isolate that does
grow on the agar should have confirmatory testing performed
to determine its vancomycin susceptibility. For confirmatory
analysis, the isolate should be either tested directly with the
BHI-V3 agar or, if there is not adequate growth to do so,
subcultured to a second BHI-V3 agar plate to maintain van-
comycin selective pressure. We feel that this is a cost-effective
algorithm that is easy to incorporate into a typical laboratory
workflow, with excellent performance for detection of VISA
isolates. Further, the use of a medium such as BHI-V3 would
nicely supplement disk diffusion testing where vancomycin in-
terpretive zone size breakpoints (other than6-mm diameter)
are currently unavailable.
We thank Karen Anderson (Clinical and Environmental Microbiol-
ogy Branch, Division of Healthcare Quality Promotion, Centers for
Disease Control and Prevention) for her assistance in providing S.
aureus isolates for the validation portion of the study.
ADDENDUM
Following the acceptance of this note, we discovered a pub-
lication by Kosowska-Shick et al. (5) that had eluded our
search efforts. In that publication, the authors describe the use
of a BHI containing 3 mg/liter vancomycin to screen for MRSA
with increased vancomycin MIC levels. While the medium was
prepared in-house instead of commercially and did not contain
the dye amaranth, it was effectively the same design as ours.
Similarly, the medium previously reported by this group had a
sensitivity of 100% for the detection of hVISA and VISA
isolates among the collection of 982 MRSA strains evaluated.
However, in their study, this screening medium carried a false
positivity rate of 94% that was reduced upon repeat testing,
whereas in our study the false positivity rate was 29.6%. This
might be due to differences in the incubation period or to the
low number (5 of 982) of VISA and hVISA strains found in the
collection tested at the Hershey Medical Center. Our plates
were read after 24 hour of incubation, whereas the previous
study evaluated growth on the screening medium after 48
hours of incubation. In addition, our collection contained 45 of
100 isolates with a vancomycin MIC  4 mg/liter. We did not
evaluate strains for the presence of the hVISA phenotype by
the use of a standardized method, but, had any hVISA strains
been identified, our false positivity rate would have declined.
We regret not having discovered this report earlier, but both
groups came independently to the same conclusion, i.e., that it
is reasonable to include a screening medium such as BHI with
3 mg/liter of vancomycin to test MRSA for evidence of reduced
susceptibility to vancomycin.
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Etest Microscan Sensititre Vitek
Blood MRSA 17 3 4 4 2
Blood MRSA 17 3 2 2 2
Blood MRSA 16 2 1 2 2
Catheter tip MRSA 17 4 4 1 0.5
Blood MRSA 18 2 2 2 1
Scalp wound MSSAa 18 3 4 4 2
Hip wound MRSA 17 4 4 2 2
Nares MRSA 22 4 4 2 1
Chest wound MRSA 18 4 4 2 2
Blood MSSA 16 2 4 2 2
Blood MSSA 24 2 2 2 2
Urine MRSA 18 4 4 4 2
Sinus MSSA 19 4 4 4 2
Tracheal
aspirate
MRSA 18 6 4 4 8
Blood MRSA 19 2 4 2 2
Blood MSSA 19 2 2 1 1
BALb MRSA 18 4 4 8 2
a MSSA, methicillin-susceptible S. aureus.
b BAL, bronchoalveolar lavage specimen.
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